15 research outputs found
Plasma miR-19b and miR-183 as Potential Biomarkers of Lung Cancer
<div><p>Lung cancer is a complex disease that often manifests at the point when treatment is not effective. Introduction of blood-based complementary diagnostics using molecular markers may enhance early detection of this disease and help reduce the burden of lung cancer. Here we evaluated the diagnostic potential of seven plasma miRNA biomarkers (miR-21, -19b, -126, -25, -205, -183, -125b) by quantitative reverse transcription PCR. Influence clinical and demographical characteristics, including age, tumor stage and cancer subtype on miRNA levels was investigated. Four miRNAs were significantly dysregulated (miR-19b, -21, -25, -183) in lung cancer patients. Combination of miR-19b and miR-183 provided detection of lung cancer with 94.7% sensitivity and 95.2% specificity (AUC = 0.990). Thus, miRNAs have shown the potential to discriminate histological subtypes of lung cancer and reliably distinguish lung cancer patients from healthy individuals.</p></div
ROC analysis of miRNA expression.
<p>Receiving Operator Characteristic (ROC) curves for individual miRNAs and combination of miR-19b and miR-183. (A)–(E) Individual miRNAs; (F) Binary logistic regression of miR-19b and miR-183. ROC curves discriminate squamous cell carcinoma (SCC), adenocarcinoma (AD) and total study population of lung cancer patients (LC) from healthy individuals (HD).</p
MiRNA expression in age groups.
<p>Box plots of relative miRNA expression levels in plasma of lung cancer patients divided into three age groups: <60 years, 60–70 years, >70 years. The expression levels of miRNAs were normalized to miR-16 using dCq method. *P = 0.004; **P = 0.007 (One-way ANOVA).</p
Survival analysis of LC patients.
<p>Kaplan-Meier survival analysis of lung cancer patients. (A)–(D) Expression of miRNAs and survival of lung cancer patients. The ‘High’ and ‘Low’ miRNA expression groups were delimited by group median dCq value for each miRNA.</p
Expression and diagnostic value of miRNA in HD and PCa patients.
<p>Analytical performance ROC analysis and statistical analysis of the results (non-parametric Mann-Whitney test) of miRNA expression in urine.</p
Appearance and size of urine EVs.
<p>(A) TEM images of EVs from urine of HD and PCa patients before and after 0.1 μm filtration. (B) Size distribution of EVs before and after 0.1 μm filtration. Mean size with error bars for range. Additional TEM images can be found in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0157566#pone.0157566.s001" target="_blank">S1 Fig</a>.</p
Total RNA in preparations of urine EVs.
<p>Bioanalyzer traces of total RNA from ERV fraction of the urine of HD (A) and PCa patient (B). The data from Agilent 2100 Bioanalyzer with 25 nt RNA fragment as an internal standard.</p